Abstract Objective To study the effects of Batroxobin on otitis media with effusion （OME） , an early stage of Adhe• sive Otitis Media （AOM） , for the purpose of expanding our understanding of the role of fibrinolysis in the pathogene• sis of AOM. Method Forty cases of OME（45 ears）were randomly selected to receive intratympanic administration of Dexamethasone at 5 mg/ml （Group 1 or G1） , Batroxobin at 1 BU/ml （Group 2 or G2）or Batroxobin at 2 BU/ml （Group 3 or G3） . Pre-and post-treatment changes in clinical symptoms, the Air conduction Hearing Threshold （AHT）in pure tone audiometry and average AHT over 0.25 to 2 kHz were compared. Results Data from 31 cases （33 ears）were available for analysis. AHTs among three groups were similar prior to treatment （P > 0.05） . The rate of normal hearing following treatment in G3 was 70% or 7／10, higher than in G1 （41.7% or 5／12）and G2 （54.5% or 6／11） （P < 0.05） . The rate of improvement following treatment was 81.8% or 9/11 and 80.0% or 8／10 in G2 and G3, respectively, higher than that in G1 （50.0% or 6／12） （P < 0.05） . Conclusions Therapeutic effects of intra• tympanic injection of Batroxobin on OME is superior to traditionally used Dexamethasone. In addition, higher concen• tration of Batroxobin appears to be superior to lower concentrations. These findings confirm that fibrinolysis plays a pivotal role in the pathogenesis of middle ear adhesion and that fibrinolytic medicine can prevent or reduce adhesion development in the middle ear.
Intruduction
Adhesive otits media（AOM）is an important cause of hearing loss. Adhesion in the middle ear is irreversible once formed. Therefore, the most effective clinical inter• vention for AOM is to prevent or mitigate adhesion for• mation in the middle ear. Currently, AOM is regarded as a later stage or sequelae and complication of all types of otitis media
［1］
. In the clinic, late stage otitis media with effusion（OME）often is seen to progress to AOM, sup• porting this view. Studies of peritoneal adhesion indi• cate that reduction of local fibrinolysis is a key fac• tor in peritoneal adhesion formation
［2，3］
. In addi• tion, the characteristics of adhesion in the peritoneal and tympanic cavities are similar. We, therefore, specu• lated that fibrinolysis also played a pivotal role in mid• dle ear adhesion ［4］ and hypothesized that, if so, the fibri• nolytic medicine, Batroxobin, would prevent or reduce adhesion formation and accelerate recovery from OME. Here, we investigate the effect of Batroxobin on OME in comparison to Dexamethasone, an agent widely used in OME treatment, in order to elucidate the role of fibrino• lysis during adhesion formation in the middle ear.
Material and Methods 1. Patient inclusion criteria: 1）reported fullness and obstruction in the ear, hearing loss and tinnitus; 2）over 0.25-2kHz, air conduction hearing threshold（AHT）on pure tone audiometry >25 dB HL, bone conduction ≤ 25dB HL and air and bone gap ≥10 dB ［5］ ；3）type B or C tympanogram；4）presence of intratympanic flu• id on tympanotomy；５）no other present diseases.
Treatment groups
Patients were randomly selected to receive intratympanic injection of dexamethasone so• dium phosphate at 5 mg／ml（Group 1 or G1） , Batroxo• bin（made in Japan）at 1 BU／ml（Group 2 or G2）or Batroxobin at 2 BU／ml （Group 3 or G3） . 
Treatment
After sterilizing the external auditory me• atus with 75% ethanol and topical tympanic membrane anesthesia， tympanotomy was performed and the middle ear drained. 0.5 ml of either dexamethasone sodium phosphate at 5 mg／ml （G1） , Batroxobin at 1 BU／ml （G2）or Batroxobin at 2 BU／ml （G3）was injected into the tympanic cavity, After the procedure, patients were placed on Cefalexin at 0.5 g tid for 5 days and followed up on the 3rd, 7th, 14th and 28th post-operation days. Treatment was repeated 1-2 times if deemed necessary. AHT was tested before and after treatment. Table 2 -3 for changes in symptoms and AHT over 0.25 to 2 kHz. Table 3 and Figure  1 for AHT changes over 0.25 to 2 kHz in three groups before and after treatment. Note: * G1 lower than G2 and G3 （P < 0.05） ; ** G3 higher than G1 and G2（P < 0.05） ; *** Preoperative AHT were less than 30 dB HL in one of the two failure cases in G3 Table. 3 Pre-and post-treatment AHT (dB HL)
Therapeutic effecacy: See

Audiometric data changes: See
· ·116 Journal of Otology 2009 Vol. 4 No. 2
Discussion
According to reports, decreased local fibrinolysis plays a pivotal role in the pathogenesis of peritoneal adhesions
［2，3］
. As the activity of plasminogen activator（PA） , the most important factor in fibrinolysis, in effusion of the middle ear, is reduced ［6, 7］ ，Effective prevention and treatment of OME with the fibrinolysis medicine, Ba• troxobin
［8］
, have been reported in an experimental model and the authors'previous works have shown that PA plays a role in adhesive formation in the middle ear ［9］ ， we hypothesize, therefore, that fibrinolysis is also an im• portant factor in the pathogenesis of middle ear adhesion through mechanisms similar to that in peritoneal adhe• sion. Adhesion formation can be caused by many fac• tors, including infection, allergy, surgery, injury, eusta• chian tube dysfunction, etc. Damage to the mucosa of middle ear leads to inflammatory responses and repair which involve several complex biological processes and at least five separate, but interrelated, systems. Mucosal damage can result in injury of vascular endothelium and subsequent exudation of all blood constituents, in• cluding fibrinogen, plasminogen and fibronectin（Fn） , all of which can collect in the middle ear. Fibrinogen re• acts with thrombin to create fibrin monomer that can po• lymerize. Fibrin polymers then come into contact with coagulation factors such as factor XIIIa and become in• soluble. Eventually, insoluble fibrin polymers interact with large proteins, such as Fn, to produce the fibrin gel matrix. Adhesion formation or adhesion-free re-epitheli• alization of the fibrin matrix is an alternative pathway, which depends on fibrinolytic activities. At sufficient levels of fibrinolytic activities, the fibrin gel matrix can be completely lysed. Otherwise, the fibrin gel matrix re• mains and serves as the progenitor to adhesions by form• ing a band or bridge between two apposed mucosa sur• faces coated with it. The band or bridge becomes the ba• sis for the organization of an adhesion. Usually, within 5 to 7 days, it can be determined whether the fibrin gel matrix has persisted or been lysed
［2-4］
, consistent with findings in animal models of middle ear adhesion forma• tion
［10］
. There are three sources of fluid in OME: blood con• tents from the middle ear mucosa discharged into the cavity, secretions arising from mucosa epithelium meta• plasia, and proliferation of mucosa glands. Related to the first source are three models of pathogenesis based on blood vessel permeability: 1) bubble proliferation, 2) loosening contact between endothelial cells, and 3) endo• thelium destruction. In mild cases, the first two condi• tions preponderate and the exudation consists of salt and low molecular weight proteins. In severe cases where the third circumstance occurs, a great variety of blood com• ponents can be exuded
［11］
. The latter two fluid source of OME typify chronic reactions where the aforemen• tioned blood vessel reaction underlies and persists throughout the inflammation process.
Fibrin （coming from fibrinogen）deposition in the mid• dle ear seems to be a prerequisite for adhesion forma• tion. Fibrinogen comes from the blood during the inflam• matory process and is a high molecular weight protein. It is exuded in severe cases that destroy the vessel' s endo• Once formed, adhesion is irreversible. Giving medicines that promote fibrinolysis to decompound fibrino• gen and dissolve gel matrix before adhesion develop• ment can prevent or reduce adhesion in OME, as well as accelerating recovery.
The current work compared the therapeutic effects be• tween Batroxobin and Dexamethasone. The conditions of the three groups in this study were similar, exhibiting equivalent hearing loss（P > 0.05） . Medical intervention prior to entering the study was also comparable as was the study methodology, allowing studying effects from pharmacological differences between the two medica• tions. The main role of Batroxobin is to promote fibrino• lysis, which is realized by decomposing fibrinogen, pro• moting the release and activity of tissue PA（tPA） , and reducing its inhibitors, such as а2 -PI, PAI
［12］
. Dexa• methasone works through its anti-inflammatory, antitox• ic and antishock capabilities and through inhibition of growth of capillaries and fibroblasts, which can prevent adhesion development at later stages of inflammation. Our results indicate that therapeutic effects of Batroxo• bin are better than those of Dexamethasone on OME, and that Batroxobin at 2 BU/ml is superior to Batroxobin at 1 BU/ml. This suggests that fibrinolysis is a major fac• tor in middle ear adhesion formation and pathogenesis of AOM and those Batroxobin-like medicines may prevent or reduce adhesion development in the middle ear.
We therefore conclude that fibrinolysis is an important factor in pathogenesis of middle ear adhesion and that application of medicines that promote fibrinolytic pro• cess and removing exuded fibrinogen in the middle ear in time can prevent／reduce adhesion formation and de• velopment of AOM.
